Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews · Gut

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 2 · 40%High 2 · 40%

Adverse events · people with moderate to severe Crohn's disease in remission

Ustekinumab showed no clear difference in adverse events compared with placebo (high certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.94 [0.87, 1.03]
2 studies · 541 participants
High

Adverse events · induction of remission in Crohn's disease

Ustekinumab showed no clear difference in adverse events compared with placebo (high certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 0.97 [0.9, 1.04]
4 studies · 2023 participants
High

Serious adverse events · people with moderate to severe Crohn's disease in remission

Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.74 [0.48, 1.15]
2 studies · 541 participants
Moderate

Serious adverse events · induction of remission in Crohn's disease

Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 0.83 [0.58, 1.2]
4 studies · 2023 participants
Moderate

Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission

Ustekinumab showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 4.93 [0.59, 41.18]
1 study · 145 participants
Low